Medical Devices Startups

BrainSightAI develops artificial intelligence tools that analyze complex MRI brain scans to support diagnosis in the neurology and mental health fields, serving clinical and healthcare providers. The Bengaluru-based company works with clinical study partners and is pursuing FDA certification for expansion into US markets.

3 investors

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions. The company focuses on improving the standard of care for patients with these disease types.

3 investors

BreezeBio develops a programmable delivery platform called NanoGalaxy for targeted delivery of genetic medicines to specific cells and tissues. The platform addresses the challenge of enabling genetic payloads to reach their target sites in the body to control biological processes.

3 investors

Bright Insight develops regulated digital health software and solutions for biopharmaceutical and medical device companies, drawing on extensive experience in data privacy and compliance.

3 investors

Brius (Brava) makes orthodontic teeth-straightening technology using its Independent Movers system, which it integrates with orthodontic practices. The product is a behind-the-teeth braces alternative for patients seeking to straighten their teeth.

3 investors

Biobeat offers a wearable chest-patch device paired with a mobile app for 24-hour ambulatory blood pressure monitoring to confirm or unmask hypertension. It automatically generates reports for care providers, supporting treatment planning and reimbursement pathways in clinical cardiology settings.

3 investors

Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.

3 investors

Camstent develops a patented Bacteriaphobic (bacteria-repelling), non-eluting polymer coating for silicon-based medical devices such as Foley catheters, endotracheal tubes, chest drain tubes, and cannulas. The coating resists bacterial colonisation and biofilm formation to help prevent hospital-acquired infections, and its coated catheters are available to NHS hospitals in the United Kingdom.

3 investors

Canopy operates an Intelligent Care Platform for oncology practices, using data-driven software to support continuous care for cancer patients and caregivers. Its tools help care teams improve patient outcomes and experience throughout the cancer journey.

3 investors

Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.

3 investors

Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms. The company serves heart failure patients and clinicians, with operations in the United States, Australia, and Germany.

3 investors

Cardiomatics is an AI-powered cloud-based medical software for analyzing Ambulatory (Holter) ECG tests, serving cardiologists and healthcare facilities across Europe. The platform uses clinically validated machine learning algorithms to automate ECG interpretation and integrate with hospital systems.

3 investors

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.

3 investors

Carecube is a medical device developed for hospitals, emergency responders, and care settings to support infectious disease response and preparedness. It was created in collaboration with frontline healthcare workers and the University of Nebraska Medical Center in the United States.

3 investors

CarrTech develops FROG (Filter Removal of Glass), an FDA-cleared all-in-one device that combines a filter and hypodermic needle in a single package for preparing injectable medications from glass ampoules. The device is aimed at medical professionals and hospitals to reduce glass-shard contamination and needle-stick injuries during medication preparation.

3 investors

Catena develops a conjugation platform for antibody-drug conjugates (ADCs) and multi-payload conjugates used in oncology for solid tumors. The company's technology enables therapeutic structures that deliver dual payloads to cancer targets.

3 investors

Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration. The company applies translational biology and drug development expertise across multiple therapeutic areas.

3 investors

Celerion is a contract research organization specializing in early phase clinical drug development, providing bioanalytical services and laboratory testing that generate clinical data for pharmaceutical clients. It focuses on early stage drug development to help clients make go/no-go decisions and bring drugs to market.

3 investors

Cellarity develops therapeutics using AI-powered multi-omics analysis to identify and correct dysfunctional cellular states, treating complex diseases by regulating genetic pathways rather than targeting single genes.

3 investors

Cellbyte automates regulatory workflows and data analysis for pharmaceutical drug launches, helping manufacturers prepare treatments for global markets faster.

3 investors

Cellply develops VivaCyte, an automated analytical platform for characterizing immune cells at single-cell resolution, used in the discovery and process development of cell therapies. The system handles sample preparation through image processing, analyzing over 100 samples per run and more than 1,000 single cells per sample.

3 investors

Celltrion is a biopharmaceutical company that researches, develops, manufactures, and markets biosimilars and novel biologic therapeutics across therapeutic areas including immunology, oncology, hematology, ophthalmology, and endocrinology. Its products include ZYMFENTRA (subcutaneous infliximab) for inflammatory bowel disease and a range of FDA-approved biosimilars.

3 investors

Centese develops Thoraguard, a digital surgical drainage system for cardiothoracic surgery that automates chest tube clog clearance and measures air leak rate and drainage volume, alerting care teams to disruptions. The system is aimed at clinicians and ICU/critical care teams to support post-operative patient monitoring and recovery.

3 investors

Child Health Imprints develops IoT devices and AI-driven predictive analytics software for neonatal intensive care units, including a bedside surveillance device (NEO), a NICU workflow platform (iNICU), and a post-discharge child growth tracking product (iCHR). Its tools capture real-time vitals data and use machine learning to predict disease onset and severity in neonates for hospitals and clinicians.

3 investors